Objective To analyze the effect and safety of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease.Methods A total of 80 patients with angina pectoris of coronary heart disease were randomly divided into a study group(40 cases)and a control group(40 cases).The control group was treated with ezetimibe alone,and the study group was treated with ezetimibe combined with clopidogrel.The clinical indicators,total cholesterol(TC),triglyceride(TG),endothelin-1(ET-1),nitric oxide(NO),and drug safety of the two groups were compared.Results After treatment,the duration of angina pectoris of(8.89±0.71)min/time in the study group was shorter than(9.32±0.86)min/time in the control group,and the frequency of angina pectoris of(2.03±0.15)times/week was lower than(4.59±0.29)times/week in the control group.The difference was statistically significant(P＜0.05).After treatment,TG and TC in the study group were(1.18±0.16)and(3.16±0.82)mmol/L,which were lower than(1.59±0.23)and(4.72±1.01)mmol/L in the control group,and the difference was statistically significant(P＜0.05).After treatment,ET-1 of(67.45±5.23)ng/L in the study group was lower than(74.16±4.12)ng/L in the control group,and NO of(82.57±5.18)μmol/L was higher than(71.73±4.15)μmol/L in the control group.The difference was statistically significant(P＜0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the study group(7.50% )and the control group(10.00% )(P＞0.05).Conclusion In the clinical treatment of angina pectoris of coronary heart disease,the combined application of ezetimibe and clopidogrel has a more obvious effect,which can improve the blood lipid level and indicators of ET-1 and NO.Moreover,the combination of drugs in patients does not cause serious adverse reactions,which has a high safety.
ClopidogrelEzetimibeAngina pectoris of coronary heart diseaseClinical efficacySafety
NETL
NSTL
万方数据
